Design, Synthesis, Biological Activity, and Molecular Modeling of Novel Spiroquinazoline Derivatives as Acetylcholinesterase Inhibitors for Alzheimer Disease

References

• L. Mohammadkhani, and M.M. Heravi, “Microwave-Assisted Synthesis of Quinazolines and Quinazolinones: An Overview,” Frontiers in Chemistry 8 (2020): 580086–38.
   PubMed Web of Science ®Google Scholar
• S. Mishra, “Quinazolinone and Quinazoline Derivatives: Synthesis and Biological Application,” in Quinazolinone and Quinazoline Derivatives, edited by A. G. Al-kaf (London: IntechOpen, 2019).
   Google Scholar
• S. Malasala, J. Gour, N. Ahmad, S. Gatadi, M. Shukla, G. Kaul, A. Dasgupta, Y.V. Madhavi, S. Chopra, and S. Nanduri, “Copper Mediated One-Pot Synthesis of Quinazolinones and Exploration of Piperazine Linked Quinazoline Derivatives as anti-Mycobacterial Agents,” RSC Advances 10, no. 71 (2020): 43533–8.
   PubMed Web of Science ®Google Scholar
• Z. Sumera, K. Imtiaz, I. Jamshed, S. Aamer, B. Sadaf, A. Naeem, and A. Zaman, “Quinazolines and Quinazolinones as Ubiquitous Structural Fragments in Medicinal Chemistry: An Update on the Development of Synthetic Methods and Pharmacological Diversification,” Bioorganic Medical Chemistry 24, no. 11 (2016): 2361–81.
   PubMed Web of Science ®Google Scholar
• E. Jafari, M.R. Khajouei, F. Hassanzadeh, G.H. Hakimelahi, and G.A. Khodarahmi, “Quinazolinone and Quinazoline Derivatives: Recent Structures with Potent Antimicrobial and Cytotoxic Activities,” Research Pharmacetical Sciences 11, no. 1 (2016): 1–14.
   PubMedGoogle Scholar
• M.F. Zayed, H.E.A. Ahmed, S. Ihmaid, A.S.M. Omar, and A.S. Abdelrahim, “Synthesis and Screening of Some New Fluorinated Quinazolinone-Sulphonamide Hybrids as Anticancer Agents,” Journal of Taibah University Medical Sciences 10, no. 3 (2015): 333–9.
   Google Scholar
• A.A. Radwan and F.K. Alanazi, “Biological Activity of Quinazolinones,” in Quinazolinone and Quinazoline Derivatives, edited by A.G. Al-kaf (Rijeka: IntechOpen, 2020).
   Google Scholar
• S.Y. Abbas, “4(3 H) -Quinazolinone Derivatives: Syntheses, Physical Properties, Chemical Reaction, and Biological Properties, A. G. Al-kaf, Ed. ” in Quinazolinone and Quinazoline Derivatives (London: IntechOpen, 2020), 1–22.
   Google Scholar
• J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole, C.M. Dixon, J.W. Kusek, H. Lepor, K.T. McVary, L.M. Nyberg, H.S. Clarke, et al, “The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia,” The New England Journal of Medicine 349, no. 25 (2003): 2387–98.
   PubMed Web of Science ®Google Scholar
• Z. Li, B. Wang, J.Q. Hou, S.-L. Huang, T.-M. Ou, J.-H. Tan, L.-K. An, D. Li, L.-Q. Gu, and Z.-S. Huang, “2-(2-indolyl-)-4(3H)-Quinazolines Derivates as New Inhibitors of AChE: Design, Synthesis, Biological Evaluation and Molecular Modelling,” Journal of Enzyme Inhibition and Medicinal Chemistry 28, no. 3 (2013): 583–92.
   PubMed Web of Science ®Google Scholar
• I. Silman and J.L. Sussman, “Acetylcholinesterase: ‘Classical’ and ‘Non-Classical’ Functions and Pharmacology,” Current Opinion in Pharmacology 5, no. 3 (2005): 293–302.
   PubMed Web of Science ®Google Scholar
• T.L. Rosenberry, “Acetylcholinesterase,” Advances in Enzymology and Related Areas of Molecular Biology 43 (1975): 103–218.
   PubMedGoogle Scholar
• R.J. Castellani, R.K. Rolston, and M.A. Smith, “Alzheimer Disease,” Disease-a-Month 56, no. 9 (2010): 484–546.
   PubMed Web of Science ®Google Scholar
• D. De. Boer, N. Nguyen, J. Mao, J. Moore, and E.J. Sorin, “A Comprehensive Review of Cholinesterase Modeling and Simulation,” Biomolecules 11, no. 4 (2021): 580.
   PubMed Web of Science ®Google Scholar
• P. Anand and B. Singh, “A Review on Cholinesterase Inhibitors for Alzheimer’s Disease,” Archives of Pharmacal Research 36, no. 4 (2013): 375–99.
   PubMed Web of Science ®Google Scholar
• H.O. Gulcan, I.E. Orhan, and B. Sener, “Chemical and Molecular Aspects on Interactions of Galanthamine and Its Derivatives with Cholinesterases,” Current Pharmaceutical Biotechnology 16, no. 3 (2015): 252–8.
   PubMed Web of Science ®Google Scholar
• M.R. Ali, M. Sadoqi, S.G. Møller, A. Boutajangout, and M. Mezei, “Assessing the Binding of Cholinesterase Inhibitors by Docking and Molecular Dynamics Studies,” Journal of Molecular Graphics & Modelling 76 (2017): 36–42.
   PubMed Web of Science ®Google Scholar
• M.A. Silva, A.S. Kiametis, and W. Treptow, “Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature,” Journal of Chemical Information and Modeling 60, no. 7 (2020): 3463–71.
   PubMed Web of Science ®Google Scholar
• C.A. Lane, J. Hardy, and J.M. Schott, “Alzheimer’s Disease,” European Journal of Neurology 25, no. 1 (2018): 59–70.
   PubMed Web of Science ®Google Scholar
• D. Silva, M. Chioua, A. Samadi, P. Agostinho, P. Garção, R. Lajarín-Cuesta, C. de Los Ríos, I. Iriepa, I. Moraleda, L. Gonzalez-Lafuente, et al, “Synthesis, Pharmacological Assessment, and Molecular Modeling of Acetylcholinesterase/Butyrylcholinesterase Inhibitors: Effect against Amyloid-β-Induced Neurotoxicity,” ACS Chemical Neuroscience 4, no. 4 (2013): 547–65.
   PubMed Web of Science ®Google Scholar
• J. Gálvez, S. Polo, B. Insuasty, M. Gutiérrez, D. Cáceres, J.H. Alzate-Morales, P. De-la-Torre, and J. Quiroga, “Design, Facile Synthesis, and Evaluation of Novel Spiro- and Pyrazolo[1,5-c]Quinazolines as Cholinesterase Inhibitors: Molecular Docking and MM/GBSA Studies,” Computational Biology and Chemistry 74 (2018): 218–29.
   PubMed Web of Science ®Google Scholar
• D. Ismail, S. Bouarab, and G. Said, “Docking, Dynamic Simulation and Quantum Mechanics Studies of Pyrazinamide Derivatives as Novel Inhibitors of Acetylcholinesterase and Butyrylcholinesterase,” Der Pharma Chemica 7 (2015): 307–21.
   Google Scholar
• Y. Bourne, P. Taylor, P.E. Bougis, and P. Marchot, “Crystal Structure of Mouse Acetylcholinesterase. A Peripheral Site-Occluding Loop in a Tetrameric Assembly,” Journal of Biological Chemistry 274, no. 5 (1999): 2963–70.
   PubMed Web of Science ®Google Scholar
• G. Campiani, C. Fattorusso, S. Butini, A. Gaeta, M. Agnusdei, S. Gemma, M. Persico, B. Catalanotti, L. Savini, V. Nacci, et al, “Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitors,” Journal of Medicinal Chemistry 48, no. 6 (2005): 1919–29.
   PubMed Web of Science ®Google Scholar
• Y. Xu, J.P. Colletier, H. Jiang, I. Silman, J.L. Sussman, and M. Weik, “Induced-Fit or Preexisting Equilibrium Dynamics? Lessons from Protein Crystallography and MD Simulations on Acetylcholinesterase and Implications for Structure-Based Drug Design,” Protein Science: A Publication of the Protein Society 17, no. 4 (2008): 601–5.
   PubMed Web of Science ®Google Scholar
• W. Alvarado, P.L. Bremer, A. Choy, H.N. Dinh, A. Eung, J. Gonzalez, P. Ly, T. Tran, K. Nakayama, J.P. Schwans, et al, “Understanding the Enzyme-Ligand Complex: Insights from All-Atom Simulations of Butyrylcholinesterase Inhibition,” Journal of Biomolecular Structure & Dynamics 38, no. 4 (2020): 1028–41.
   PubMed Web of Science ®Google Scholar
• P.H. Axelsen, M. Harel, I. Silman, and J.L. Sussman, “Structure and Dynamics of the Active Site Gorge of Acetylcholinesterase: Synergistic Use of Molecular Dynamics Simulation and X-Ray Crystallography,” Protein Science: A Publication of the Protein Society 3, no. 2 (1994): 188–97.
   PubMed Web of Science ®Google Scholar
• R. Rohs, I. Bloch, H. Sklenar, and Z. Shakked, “Molecular Flexibility in ab Initio Drug Docking to DNA: Binding-Site and Binding-Mode Transitions in All-Atom Monte Carlo Simulations,” Nucleic Acids Research 33, no. 22 (2005): 7048–57.
   PubMed Web of Science ®Google Scholar
• I.A. Guedes, C.S. de Magalhães, and L.E. Dardenne, “Receptor-Ligand Molecular Docking,” Biophysical Reviews 6, no. 1 (2014): 75–87.
   PubMedGoogle Scholar
• K. Revathy and A. Lalitha, “P-TSA-Catalyzed Synthesis of Spiroquinazolinones,” Journal of the Iranian Chemical Society 12, no. 11 (2015): 2045–9.
   Web of Science ®Google Scholar
• M. Morgen, “Mild Mono-Acylation of 4,5-Diiodoimidazole: Preparation of 1-(5-Iodo-1H-Imidazole-4-yl)Pent-4-en-1-One,” Organic Syntheses 98 (2021): 171–93.
   Web of Science ®Google Scholar
• G.L. Ellman, K.D. Courtney, V. Andres, and R.M. Feather-Stone, “A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity,” Biochemical Pharmacology 7, no. 2 (1961): 88–95.
   PubMed Web of Science ®Google Scholar
• G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson, “AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility,” Journal of Computational Chemistry 30, no. 16 (2009): 2785–91.
   PubMed Web of Science ®Google Scholar
• J. Dennington, R. Keith, and T. Millam, GaussView.” Version 5.0.8 (Shawnee Mission, KS: Semichem Inc., 2009).
   Google Scholar
• J. Frisch, M. Trucks, G. Schlegel, H. Scuseria, G. Robb, M. Cheeseman, J. Montgomery, Jr, J. Vreven, T. Kudin, and K. Burant, Gaussian 03. (Wallingford, CT: Gaussian, Inc., 2004).
   Google Scholar
• J. Stewart, “Optimization of Parameters for Semiempirical Methods V: Modification of NDDO Approximations and Application to 70 Elements,” Journal of Molecular Modeling 13, no. 12 (2007): 1173–213.
   PubMed Web of Science ®Google Scholar
• A.J.A. Docking, “Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function,” Journal of Computational Chemistry 19, no. 14 (1998): 639–1662.
   Web of Science ®Google Scholar
• E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin, “UCSF Chimera—a Visualization System for Exploratory Research and Analysis,” Journal of Computational Chemistry 25, no. 13 (2004): 1605–12.
   PubMed Web of Science ®Google Scholar
• M. Šudomová, S.T.S. Hassan, H. Khan, M. Rasekhian, and S.M. Nabavi, “A Multi-Biochemical and in Silico Study on anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation,” Biomolecules 9, no. 9 (2019): 392.
   PubMed Web of Science ®Google Scholar
• L.-N.-T. Giang, T. Nga, P.T. Hai, A. Dang, T. Huong, T. Thu, H. Sa, and N. Tuyen, “Synthesis and Biological Evaluation of Novel Quinazoline-Triazole Hybrid Compounds with Potential Use in Alzheimer’s Disease,” Bioorganic & Medicinal Chemistry Letters 30, no. 18 (2020): 127404.
   PubMed Web of Science ®Google Scholar
• N. Guzior, A. Wieckowska, D. Panek, and B. Malawska, “Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease,” Current Medicinal Chemistry 22, no. 3 (2015): 373–404.
   PubMed Web of Science ®Google Scholar
• T. Mohamed, M.K. Mann, and P.P.N. Rao, “Application of Quinazoline and Pyrido[3,2-: D] Pyrimidine Templates to Design Multi-Targeting Agents in Alzheimer’s Disease,” RSC Advances 7, no. 36 (2017): 22360–8.
   Web of Science ®Google Scholar